Roche Again Extends $5.7B Offer To Illumina Shareholders
Last month, Illumina's board unanimously rejected Roche's $44.50 per share offer, which was set to expire March 23. It will now run until April 20. No terms have changed; Roche has called its current cash offer a fair price for a company that faces “increasing headwinds.”
The bid represents a...
To view the full article, register now.